Properties and synthesis of 2-{2-fluoro (or bromo)-4-[(2-oxocyclopentyl) methyl]phenyl}propanoic acid: Nonsteroidal anti-inflammatory drugs with low membrane permeabilizing and gastric lesion-producing activities

Journal of Medicinal Chemistry

Volumn 53, Issue 21, 2010, Pages 7879-7882

  Yamakawa, Naoki ^a   Suemasu, Shintaro ^a   Matoyama, Masaaki ^a   Kimoto, Ayumi ^a   Takeda, Miho ^a   Tanaka, Ken Ichiro ^a   Ishihara, Tomoaki ^a   Katsu, Takashi ^b   Okamoto, Yoshinari ^a   Otsuka, Masami ^a   Mizushima, Tohru ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 BROMO 4 [(2 OXOCYCLOPENTYL)METHYL]PHENYL]PROPANOIC ACID; 2 [2 FLUORO 4 [(2 OXOCYCLOPENTYL)METHYL]PHENYL]PROPANOIC ACID; BROMO LOXOPROFEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FLUORO LOXOPROFEN; LOXOPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG PENETRATION; DRUG SAFETY; DRUG SYNTHESIS; MEMBRANE PERMEABILITY; NONHUMAN; RAT; STOMACH LESION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL MEMBRANE PERMEABILITY; CYCLOOXYGENASE INHIBITORS; GASTRIC MUCOSA; GASTROINTESTINAL HEMORRHAGE; HUMANS; PHENYLPROPIONATES; PRODRUGS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78149262003     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101116s     Document Type: Article

References (23)

1. Smalley, W. E.; Ray, W. A.; Daugherty, J. R.; Griffin, M. R. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons Am. J. Epidemiol. 1995, 141, 539-545
2. Hawkey, C. J. Nonsteroidal anti-inflammatory drug gastropathy Gastroenterology 2000, 119, 521-535
3. Barrier, C. H.; Hirschowitz, B. I. Controversies in the detection and management of nonsteroidal antiinflammatory drug-induced side effects of the upper gastrointestinal tract Arthritis Rheum. 1989, 32, 926-932
4. Fries, J. F.; Miller, S. R.; Spitz, P. W.; Williams, C. A.; Hubert, H. B.; Bloch, D. A. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use Gastroenterology 1989, 96, 647-655
5. Kujubu, D. A.; Fletcher, B. S.; Varnum, B. C.; Lim, R. W.; Herschman, H. R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue J. Biol. Chem. 1991, 266, 12866-12872
6. Xie, W. L.; Chipman, J. G.; Robertson, D. L.; Erikson, R. L.; Simmons, D. L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 2692-2696
7. Silverstein, F. E.; Faich, G.; Goldstein, J. L.; Simon, L. S.; Pincus, T.; Whelton, A.; Makuch, R.; Eisen, G.; Agrawal, N. M.; Stenson, W. F.; Burr, A. M.; Zhao, W. W.; Kent, J. D.; Lefkowith, J. B.; Verburg, K. M.; Geis, G. S. Gastrointestinal Toxicity with Celecoxib vs Nonsteroidal Anti-Inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS study, a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study JAMA, J. Am. Med. Assoc. 2000, 284, 1247-1255
8. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos, V. R.; Davis, B.; Day, R.; Ferraz, M. B.; Hawkey, C. J.; Hochberg, M. C.; Kvien, T. K.; Schnitzer, T. J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group N. Engl. J. Med. 2000, 343, 1520-1528 p 1522 following p 1528.
9. FitzGerald, G. A.; Patrono, C. The coxibs, selective inhibitors of cyclooxygenase-2 N. Engl. J. Med. 2001, 345, 433-442
10. Mukherjee, D.; Nissen, S. E.; Topol, E. J. Risk of cardiovascular events associated with selective COX-2 inhibitors JAMA, J. Am. Med. Assoc. 2001, 286, 954-959 (Pubitemid 33010342)
11. Mukherjee, D. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events Biochem. Pharmacol. 2002, 63, 817-821
12. McAdam, B. F.; Catella, L. F.; Mardini, I. A.; Kapoor, S.; Lawson, J. A.; FitzGerald, G. A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 Proc. Natl. Acad. Sci. U.S.A 1999, 96, 272-277
13. Catella, L. F.; McAdam, B.; Morrison, B. W.; Kapoor, S.; Kujubu, D.; Antes, L.; Lasseter, K. C.; Quan, H.; Gertz, B. J.; FitzGerald, G. A. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids J. Pharmacol. Exp. Ther. 1999, 289, 735-741
14. Belton, O.; Byrne, D.; Kearney, D.; Leahy, A.; Fitzgerald, D. J. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis Circulation 2000, 102, 840-845
15. Lichtenberger, L. M. Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited Biochem. Pharmacol. 2001, 61, 631-637
16. Tomisato, W.; Tsutsumi, S.; Hoshino, T.; Hwang, H. J.; Mio, M.; Tsuchiya, T.; Mizushima, T. Role of direct cytotoxic effects of NSAIDs in the induction of gastric lesions Biochem. Pharmacol. 2004, 67, 575-585
17. Tomisato, W.; Tanaka, K.; Katsu, T.; Kakuta, H.; Sasaki, K.; Tsutsumi, S.; Hoshino, T.; Aburaya, M.; Li, D.; Tsuchiya, T.; Suzuki, K.; Yokomizo, K.; Mizushima, T. Membrane permeabilization by non-steroidal anti-inflammatory drugs Biochem. Biophys. Res. Commun. 2004, 323, 1032-1039
18. Misaka, E.; Yamaguchi, T.; Iizuka, Y.; Kamoshida, K.; Kojima, T.; Kobayashi, K.; Endo, Y.; Misawa, Y.; Lobayashi, S.; Tanaka, K. Anti-inflammatory, Analgesic and Antipyretic Activities of Sodium 2-[4-(2-Oxocyclopentan-1-ylmethyl)phenyl] Propionate Dihydrate (CS-600)* Pharmacometrics 1981, 21, 753-771
19. Kawano, S.; Tsuji, S.; Hayashi, N.; Takei, Y.; Nagano, K.; Fusamoto, H.; Kamada, T. Effects of loxoprofen sodium, a newly synthesized non-steroidal anti-inflammatory drug, and indomethacin on gastric mucosal haemodynamics in the human J. Gastroenterol. Hepatol. 1995, 10, 81-85
20. Sugimoto, M.; Kojima, T.; Asami, M.; Iizuka, Y.; Matsuda, K. Inhibition of prostaglandin production in the inflammatory tissue by loxoprofen-Na, an anti-inflammatory prodrug Biochem. Pharmacol. 1991, 42, 2363-2368
21. Yamakawa, N.; Suemasu, S.; Kimoto, A.; Arai, Y.; Ishihara, T.; Yokomizo, K.; Okamoto, Y.; Otsuka, M.; Tanaka, K.; Mizushima, T. Low direct cytotoxicity of loxoprofen on gastric mucosal cells Biol. Pharm. Bull. 2010, 33, 398-403
22. Gierse, J. K.; Zhang, Y.; Hood, W. F.; Walker, M. C.; Trigg, J. S.; Maziasz, T. J.; Koboldt, C. M.; Muhammad, J. L.; Zweifel, B. S.; Masferrer, J. L.; Isakson, P. C.; Seibert, K. Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity J. Pharmacol. Exp. Ther. 2005, 312, 1206-1212
23. Sekiguchi, M.; Shirasaka, M.; Konno, S.; Kikuchi, S. Analgesic effect of percutaneously absorbed non-steroidal anti-inflammatory drugs: an experimental study in a rat acute inflammation model BMC Musculoskeletal Disord. 2008, 9, 15